Brokerages forecast that Teva Pharmaceutical Industries Limited (NYSE:TEVA) will announce $0.80 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Teva Pharmaceutical Industries’ earnings, with estimates ranging from $0.73 to $1.00. Teva Pharmaceutical Industries reported earnings of $1.38 per share in the same quarter last year, which suggests a negative year over year growth rate of 42%. The firm is scheduled to announce its next earnings report on Monday, February 12th.

On average, analysts expect that Teva Pharmaceutical Industries will report full year earnings of $3.84 per share for the current financial year, with EPS estimates ranging from $3.78 to $3.88. For the next year, analysts expect that the business will report earnings of $2.79 per share, with EPS estimates ranging from $2.50 to $3.02. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that that provide coverage for Teva Pharmaceutical Industries.

A number of brokerages have recently weighed in on TEVA. BTIG Research upgraded Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $24.00 price objective on the stock in a research note on Monday, September 11th. TheStreet lowered Teva Pharmaceutical Industries from a “c-” rating to a “d+” rating in a research note on Friday, August 25th. Credit Suisse Group restated an “underperform” rating and set a $8.00 price objective (down previously from $14.00) on shares of Teva Pharmaceutical Industries in a research note on Monday, November 6th. Goldman Sachs Group restated a “neutral” rating and set a $21.00 price objective (down previously from $28.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 31st. Finally, Susquehanna Bancshares lowered their price objective on Teva Pharmaceutical Industries from $20.00 to $14.00 and set a “positive” rating on the stock in a research note on Monday, November 6th. Seven research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $21.65.

Large investors have recently made changes to their positions in the company. Exane Derivatives acquired a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at about $571,000. Korea Investment CORP increased its position in Teva Pharmaceutical Industries by 14.3% in the 3rd quarter. Korea Investment CORP now owns 244,774 shares of the company’s stock valued at $4,308,000 after buying an additional 30,674 shares in the last quarter. Financial Counselors Inc. increased its position in Teva Pharmaceutical Industries by 5.7% in the 2nd quarter. Financial Counselors Inc. now owns 140,599 shares of the company’s stock valued at $4,671,000 after buying an additional 7,571 shares in the last quarter. Private Capital Management Inc. increased its position in Teva Pharmaceutical Industries by 51.3% in the 3rd quarter. Private Capital Management Inc. now owns 26,100 shares of the company’s stock valued at $459,000 after buying an additional 8,850 shares in the last quarter. Finally, Lockheed Martin Investment Management Co. bought a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at about $317,000. 52.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries (NYSE:TEVA) opened at $15.06 on Wednesday. Teva Pharmaceutical Industries has a 52-week low of $10.85 and a 52-week high of $38.31. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. The company has a market capitalization of $15,500.00, a P/E ratio of 3.52 and a beta of 0.55.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be issued a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a yield of 2.26%. The ex-dividend date of this dividend is Monday, November 27th. Teva Pharmaceutical Industries’s payout ratio is presently -12.27%.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/06/zacks-brokerages-anticipate-teva-pharmaceutical-industries-limited-teva-to-post-0-80-earnings-per-share.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.